Skip to main content
. Author manuscript; available in PMC: 2023 Mar 2.
Published in final edited form as: Mol Cancer Res. 2022 Sep 2;20(9):1429–1442. doi: 10.1158/1541-7786.MCR-22-0085

Figure 6: NVP 231 synergizes with cisplatin on Mut KRAS NSCLC cells in a VDAC-dependent manner.

Figure 6:

(A) Clonogenic cell survival assay was performed from A549 cells (LUAD-derived) treated with varying concentrations of NVP 231 (0-350 nM) for 8 hours, then with varying concentration of cisplatin (Cis) for additional 16 hours. (B) Synergistic curve was generated from the half-maximal effective concentration (EC50) of NVP/cisplatin on cell survival. (C) Cell survival assay was performed from A549 cells transfected with control or VDAC1 siRNA (siCon or siVD1) for 48 hours followed by 8-hour-vehicle (Veh) or NVP (300 nM) then 16-hour-Veh or Cis- (0.5 μM) treatment. Data in (A) and (C) are means ± SD; n = 4 from two independent occasions. Data in (B) are EC50 values calculated from mean values in (A). *p<0.0005. Unless otherwise noted by an * or depicted p-value, data are not significant between depicted groups; p>0.05.